The objective of this study was to determine the effectiveness of Telo95 in halting the shortening of telomere length as measured through blood samples before and after product use.
This study was a randomized controlled design that included 50 healthy adults. Qualified subjects provided a small blood sample via finger stick at their baseline visit. The blood samples were sent to Telomere Diagnostics Inc. for analysis of telomere length, which is used to calculate average telomere length (ATL). Subjects were randomized into one of two treatment groups: test article once per day (group A) or twice per day (group B). Subject were provided the test article, a diary to ensure compliance and instructions for use of the test product.
All 50 participants completed the study, with Group A decreasing their TeloYear age on average by 7.43 years, and Group B decreasing their Telo-Year age by 8.52 years. ATL showed a baseline measurement of 0.85 but after taking the product for six months it increased to 0.95. Group B baseline ATL measured 0.82 at baseline and increased to 0.94 post six months of test article usage.
These results suggest that Telos95 supplementation can be an effective and safe approach to halt the shortening of telomere length.
Ahmad Alkayali, CEO of Certified Nutraceuticals commented: “This is the longevity breakthrough supplement of the century. The human study is the first of its kind to confirm efficacy on telomere health and we are not aware of any other human study on natural supplements that exists. CN is planning to market this unique supplement worldwide.”